Company Profiles

driven by the PitchBook Platform

Arvinas

Description

Developer of protein degradation therapeutics created to degrade and destroy disease-causing proteins via the body's own protein disposal system. The company's protein degradation therapeutics are formed by developing small-molecule strategies aimed at removing unwanted cellular proteins, enabling healthcare professionals treat cancer, pro-inflammatory, autoimmune disorders and rare diseases by eliminate disease-causing proteins from the body.

2013

Founded

PRIVATE

Status

Series B

Latest Deal Type

$41.6M

Latest Deal Amount

$62.4M

Total Amount Raised

8

Investors

Description

Developer of protein degradation therapeutics created to degrade and destroy disease-causing proteins via the body's own protein disposal system. The company's protein degradation therapeutics are formed by developing small-molecule strategies aimed at removing unwanted cellular proteins, enabling healthcare professionals treat cancer, pro-inflammatory, autoimmune disorders and rare diseases by eliminate disease-causing proteins from the body.

Website:

www.arvinas.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

5 Science Park 395 Winchester Avenue New Haven, CT 06511United States +1 (203) 535-1456
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Arvinas's full profile, request a free trial.

    Arvinas Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Arvinas Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Arvinas Investors (8)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    5AM VenturesVenture CapitalMinority000 0000000 0000
    Canaan PartnersVenture CapitalMinority000 0000000 0000
    Connecticut InnovationsVenture CapitalMinority000 0000000 0000
    Elm Street VenturesPE/BuyoutMinority000 0000000 0000
    New Leaf Venture PartnersVenture CapitalMinority000 0000000 0000
    5AM Ventures Venture Capital
    Canaan Partners Venture Capital
    Connecticut Innovations Venture Capital
    Elm Street Ventures PE/Buyout
    New Leaf Venture Partners Venture Capital

    Arvinas Executive Team (14)

    NameTitleBoard
    Seat
    Contact
    Info
    Manny Litchman MDChief Executive Officer, President & Board Member
    Sean CassidyChief Financial Officer
    Robert Kleinfield Ph.DChief Development Officer
    Craig Crews Ph.DFounder & Chief Scientific Advisor
    Jim Winkler Ph.DChief Scientific Officer
    Manny Litchman MD Chief Executive Officer, President & Board Member
    Sean Cassidy Chief Financial Officer
    Robert Kleinfield Ph.D Chief Development Officer
    Craig Crews Ph.D Founder & Chief Scientific Advisor
    Jim Winkler Ph.D Chief Scientific Officer

    Arvinas Board Members (9)

    NameRepresentingRoleSinceContact
    Info
    Andrew Levin Ph.DRA Capital ManagementManaging Director000 0000
    Bradley MargusSelfBoard Member000 0000
    Jonathan Soderstrom Ph.DSelfBoard Member000 0000
    Kush Parmar Ph.D5AM VenturesManaging Partner000 0000
    Liam Ratcliffe Ph.DNew Leaf Venture PartnersManaging Director & General Partner000 0000
    Andrew Levin Ph.D Managing Director RA Capital Management
    Bradley Margus Board Member Self
    Jonathan Soderstrom Ph.D Board Member Self
    Kush Parmar Ph.D Managing Partner 5AM Ventures
    Liam Ratcliffe Ph.D Managing Director & General Partner New Leaf Venture Partners
    Request full access to PitchBook